MENU
SNY
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

SNY stock forecast, quote, news & analysis

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases... Show more

SNY
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SNY with price predictions
Sep 08, 2026

SNY in upward trend: 10-day moving average crossed above 50-day moving average on August 17, 2026

The 10-day moving average for SNY crossed bullishly above the 50-day moving average on August 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in of 302 cases, the price rose further within the following month. The odds of a continued upward trend are .

SNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 276 cases where SNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SNY moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNY as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SNY turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

SNY moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.276) is normal, around the industry mean (19.020). P/E Ratio (22.749) is within average values for comparable stocks, (31.910). Projected Growth (PEG Ratio) (28.486) is also within normal values, averaging (9.778). SNY has a moderately high Dividend Yield (0.056) as compared to the industry average of (0.029). P/S Ratio (1.827) is also within normal values, averaging (4.037).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.

A.I.Advisor
published Dividends

SNY paid dividends on June 03, 2026

Sanofi ADS SNY Stock Dividends
А dividend of $2.42 per share was paid with a record date of June 03, 2026, and an ex-dividend date of May 04, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 195.65B. The market cap for tickers in the group ranges from 72.83K to 1T. LLY holds the highest valuation in this group at 1T. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -6%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 7%. AMRN experienced the highest price growth at 3%, while MDCX experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was 19% and the average quarterly volume growth was -3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 23
P/E Growth Rating: 56
Price Growth Rating: 40
SMR Rating: 59
Profit Risk Rating: 63
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
SNY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a producer of pharmaceutical products

Industry PharmaceuticalsMajor

Profile
Details
Industry
Pharmaceuticals Major
Address
46, Avenue de la Great Army
Phone
+33 153774000
Employees
74846
Web
https://www.sanofi.com
SNY in upward trend: 10-day moving average crossed above 50-day moving average on August 17, 2026